Patents by Inventor Ihsan Gursel

Ihsan Gursel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Suppressors of CpG oligonucleotides and methods of use
    Patent number: 9163244
    Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: October 20, 2015
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dennis M. Klinman, Rainald Zeuner, Mayda Gursel, Ihsan Gursel, Daniela Verthelyi
  • SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
    Publication number: 20140134233
    Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
    Type: Application
    Filed: September 13, 2013
    Publication date: May 15, 2014
    Applicant: The Government of the United States of America as represented by the Secretary of the Department of
    Inventors: Dennis M. Klinman, Rainald Zeuner, Mayda Gursel, Ihsan Gursel, Daniela Verthelyi
  • Suppressors of CpG oligonucleotides and methods of use
    Patent number: 8580944
    Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: November 12, 2013
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dennis M. Klinman, Rainald Zeuner, Mayda Gursel, Ihsan Gursel, Daniela Verthelyi
  • Method of treating inflammatory arthropathies with supressors of CPG oligonucleotides
    Patent number: 8557789
    Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: October 15, 2013
    Assignee: The United States of America as represented by the Secretary of the Development of Health and Human Services
    Inventors: Dennis Klinman, Rainald Zeuner, Daniela Verthelyi, Ihsan Gursel, Mayda Gursel
  • Methods of altering an immune response induced by CpG oligodeoxynucleotides
    Patent number: 8470342
    Abstract: It is disclosed herein that agents that affect the activity and/or expression of CXCL16 can be used to alter the uptake of D-type CpG oligodeoxynucleotides (D ODNs). Methods of inducing an immune response are disclosed that include administering agents that increase the activity and/or expression of CXCL16 and a D ODN. Methods of decreasing an immune response to a CpG ODN are also disclosed. These methods include administering an agent that decreases the activity and/or expression of CXCL16. Compositions including one or more D-type ODNs and an agent that modulates that activity and/or expression of CXCL16 are provided.
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: June 25, 2013
    Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Dennis M. Klinman, Mayda Gursel, Ihsan Gursel
  • METHOD OF TREATING INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF CPG OLIGONUCLEOTIDES
    Publication number: 20130018089
    Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 17, 2013
    Inventors: Dennis Klinman, Rainald Zeuner, Daniela Verthelyi, Ihsan Gursel, Mayda Gursel
  • Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
    Patent number: 8288359
    Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: October 16, 2012
    Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dennis Klinman, Rainald Zeuner, Daniela Verthelyi, Ihsan Gursel, Mayda Gursel
  • SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
    Publication number: 20120258144
    Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
    Type: Application
    Filed: June 21, 2012
    Publication date: October 11, 2012
    Inventors: Dennis M. Klinman, Rainald Zeuner, Mayda Gursel, Ihsan Gursel, Daniela Verthelyi
  • Suppressors of CpG oligonucleotides and methods of use
    Patent number: 8227438
    Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: July 24, 2012
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dennis M. Klinman, Rainald Zeuner, Mayda Gursel, Ihsan Gursel, Daniela Verthelyi
  • METHOD OF TREATING INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF CPG OLIGONUCLEOTIDES
    Publication number: 20110201676
    Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
    Type: Application
    Filed: April 25, 2011
    Publication date: August 18, 2011
    Inventors: Dennis Klinman, Rainald Zeuner, Daniela Verthelyi, Ihsan Gursel, Mayda Gursel
  • Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
    Patent number: 7951786
    Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
    Type: Grant
    Filed: November 28, 2008
    Date of Patent: May 31, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Dennis Klinman, Rainald Zeuner, Daniela Verthelyi, Ihsan Gursel, Mayda Gursel
  • METHODS OF ALTERING AN IMMUNE RESPONSE INDUCED BY CPG OLIGODEOXYNUCLEOTIDES
    Publication number: 20110110883
    Abstract: It is disclosed herein that agents that affect the activity and/or expression of CXCL16 can be used to alter the uptake of D-type CpG oligodeoxynucleotides (D ODNs). Methods of inducing an immune response are disclosed that include administering agents that increase the activity and/or expression of CXCL16 and a D ODN. Methods of decreasing an immune response to a CpG ODN are also disclosed. These methods include administering an agent that decreases the activity and/or expression of CXCL16. Compositions including one or more D-type ODNs and an agent that modulates that activity and/or expression of CXCL16 are provided.
    Type: Application
    Filed: January 12, 2011
    Publication date: May 12, 2011
    Inventors: Dennis M. Klinman, Mayda Gursel, Ihsan Gursel
  • Methods of altering an immune response induced by CpG oligodeoxynucleotides
    Patent number: 7892569
    Abstract: It is disclosed herein that agents that affect the activity and/or expression of CXCL16 can be used to alter the uptake of D-type CpG oligodeoxynucleotides (D ODNs). Methods of inducing an immune response are disclosed that include administering agents that increase the activity and/or expression of CXCL16 and a D ODN. Methods of decreasing an immune response to a CpG ODN are also disclosed. These methods include administering an agent that decreases the activity and/or expression of CXCL16. Compositions including one or more D-type ODNs and an agent that modulates that activity and/or expression of CXCL16 are provided.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: February 22, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Dennis M. Klinman, Mayda Gursel, Ihsan Gursel
  • USE OF STERICALLY STABILIZED CATIONIC LIPOSOMES TO EFFICIENTLY DELIVER CPG OLIGONUCLEOTIDES IN VIVO
    Publication number: 20100104507
    Abstract: Sterically stabilized cationic liposomes (SSCL) encapsulating a K type oligodeoxynucleotide (ODN) including a CpG motif are disclosed. These SSCL encapuslating a K type ODN can be used to effectively deliver the ODN to a cell. A novel method is also disclosed for producing the SSCL encapsulating the K type ODN. Administration of the SSCL encapsulating a K type ODN and a chemotherapeutic agent, such as a chimeric molecule comprising a targeting molecule selected from the group consisting of an IL-13, and an anti-IL-13 receptor antibody; and an effector molecule selected from the group consisting of a Pseudomonas exotoxin, a Diphtheria toxin, and a radionuclide, can be used to dramatically reduce the growth of solid tumors.
    Type: Application
    Filed: December 24, 2009
    Publication date: April 29, 2010
    Inventors: Dennis M. Klinman, Ihsan Gursel, Ken J. Ishii, Koji Kawakami, Bharat H. Joshi, Raj K. Puri
  • Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
    Patent number: 7666674
    Abstract: Sterically stabilized cationic liposomes (SSCL) encapsulating a K type oligodeoxynucleotide (ODN) including a CpG motif are disclosed. These SSCL encapuslating a K type ODN can be used to effectively deliver the ODN to a cell. A novel method is also disclosed for producing the SSCL encapsulating the K type ODN. Administration of the SSCL encapsulating a K type ODN and a chemotherapeutic agent, such as a chimeric molecule comprising a targeting molecule selected from the group consisting of an IL-13, and an anti-IL-13 receptor antibody; and an effector molecule selected from the group consisting of a Pseudomonas exotoxin, a Diphtheria toxin, and a radionuclide, can be used to dramatically reduce the growth of solid tumors.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: February 23, 2010
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dennis M. Klinman, Ihsan Gursel, Ken J. Ishii
  • SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
    Publication number: 20090208468
    Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
    Type: Application
    Filed: February 27, 2009
    Publication date: August 20, 2009
    Inventors: Dennis M. Klinman, Rainald Zeuner, Mayda Gursel, Ihsan Gursel, Daniela Verthelyi
  • METHOD OF TREATING INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF CPG OLIGONUCLEOTIDES
    Publication number: 20090142310
    Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
    Type: Application
    Filed: November 28, 2008
    Publication date: June 4, 2009
    Inventors: Dennis Klinman, Rainald Zeuner, Daniela Verthelyi, Ihsan Gursel, Mayda Gursel
  • Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
    Patent number: 7514415
    Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: April 7, 2009
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Dennis Klinman, Rainald Zeuner, Daniela Verthelyi, Ihsan Gursel, Mayda Gursel
  • Suppressors of CpG oligonucleotides and methods of use
    Patent number: 7514414
    Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
    Type: Grant
    Filed: September 24, 2002
    Date of Patent: April 7, 2009
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Dennis M. Klinman, Rainald Zeuner, Mayda Gursel, Ihsan Gursel, Daniela Verthelyi
  • Methods of Altering an Immune Response Induced by Cpg Oligodeoxynucleotides
    Publication number: 20080249056
    Abstract: It is disclosed herein that agents that affect the activity and/or expression of CXCL16 can be used to alter the uptake of D-type CpG oligodeoxynucleotides (D ODNs). Methods of inducing an immune response are disclosed that include administering agents that increase the activity and/or expression of CXCL16 and a D ODN. Methods of decreasing an immune response to a CpG ODN are also disclosed. These methods include administering an agent that decreases the activity and/or expression of CXCL16. Compositions including one or more D-type ODNs and an agent that modulates that activity and/or expression of CXCL16 are provided.
    Type: Application
    Filed: August 28, 2006
    Publication date: October 9, 2008
    Inventors: Dennis M. Klinman, Mayda Gursel, Ihsan Gursel